(Reuters) - The Federal Trade Commission said makers of branded drugs that settle patent challenges by promising not to launch their own generic alternatives are using such agreements to delay generic competition.https://mf.feeds.reuters.com/c/871/f/...258fb9b/mf.gif
https://da.feedsportal.com/r/13926315...326-327/a2.imghttps://pi.feedsportal.com/r/13926315...26-327/a2t.img
More...
